mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagne, Lilin Lai, Juan I. Moliva, Barbara Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds, Shayne F. Andrew, Dillon R. Flebbe, Evan Lamb, Saule T. Nurmukhambetova, Samantha J. Provost, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, Alex Van Ry, Zackery FlinchbaughTimothy S. Johnston, Elham Bayat Mokhtari, Prakriti Mudvari, Amy R. Henry, Farida Laboune, Becky Chang, Maciel Porto, Jaclyn Wear, Gabriela S. Alvarado, Seyhan Boyoglu-Barnum, John Paul M. Todd, Bridget Bart, Anthony Cook, Alan Dodson, Laurent Pessaint, Katelyn Steingrebe, Sayda Elbashir, Manjari Sriparna, Andrew Pekosz, Hanne Andersen, Kai Wu, Darin K. Edwards, Swagata Kar, Mark G. Lewis, Eli Boritz, Ian N. Moore, Andrea Carfi, Mehul S. Suthar, Adrian McDermott, Mario Roederer, Martha C. Nason, Nancy J. Sullivan, Daniel C. Douek, Barney S. Graham, Robert A. Seder

Research output: Contribution to journalArticlepeer-review


B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna’s mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log10 reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log10 reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.

Original languageEnglish (US)
Pages (from-to)1306-1315
Number of pages10
JournalNature Immunology
Issue number10
StatePublished - Oct 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates'. Together they form a unique fingerprint.

Cite this